Holen Sie sich die Stockscreener-App
20.89
0.79%
0.125
Pacira Biosciences Inc Aktie (PCRX) Neueste Nachrichten
Volume Recap: Is Pacira BioSciences Inc a good ESG investment2025 Big Picture & Reliable Entry Point Trade Alerts - baoquankhu1.vn
Pacira partners with LG Chem to make EXPAREL® available in select APAC markets - BioSpectrum Asia
Pacira BioSciences, Inc. (PCRX) Investigation: Bronstein, Gewirtz & Grossman, LLC Encourages Shareholders to Contact the Firm to Learn More About the Investigation - ACCESS Newswire
DOMA Perpetual Capital to offer nominees for Pacira BioSciences board - MSN
Bronstein, Gewirtz & Grossman, LLC Initiates an Investigation into Allegations Against Pacira BioSciences, Inc. (PCRX) And Encourages Stockholders to Reach Out - ACCESS Newswire
Revenues Working Against Pacira BioSciences, Inc.'s (NASDAQ:PCRX) Share Price Following 28% Dive - simplywall.st
Benign Growth For Pacira BioSciences, Inc. (NASDAQ:PCRX) Underpins Stock's 28% Plummet - 富途资讯
Pacira BioSciences Inc (PCRX) Stock Price Down 5.4% on Jan 16 - GuruFocus
Market Outlook: Is Great Elm Group Inc subject to activist investor interestPortfolio Performance Summary & Smart Swing Trading Alerts - baoquankhu1.vn
Pacira BioSciences (NASDAQ:PCRX) Hits New 52-Week LowTime to Sell? - MarketBeat
Do Options Traders Know Something About Pacira BioSciences Stock We Don't? - TradingView — Track All Markets
Bronstein, Gewirtz & Grossman, LLC Is Investigating Pacira BioSciences, Inc. (PCRX) And Encourages Stockholders to Connect - ACCESS Newswire
Pacira BioSciences (NASDAQ:PCRX) Shares Down 6.9%What's Next? - MarketBeat
Pacira drops after adjusting 2025 revenue below consensus - MSN
PCRX, LG Chem Partner to Expand Exparel Reach Across the Asia-Pacific - Finviz
Pacira BioSciences Signs Deal With LG Chem To Commercialize EXPAREL In Select Asia-Pacific Markets - Nasdaq
LG Chem to distribute Pacira’s EXPAREL in Asian-Pacific markets By Investing.com - Investing.com India
LG Chem to distribute Pacira’s EXPAREL in Asian-Pacific markets - Investing.com
Pacira Announces Agreement with LG Chem to Make EXPAREL® Available in Select Asian-Pacific Markets - The Manila Times
Opioid-sparing EXPAREL to reach patients in South Korea and Thailand - Stock Titan
Pacira BioSciences, Inc. (PCRX) Stock Analysis: Exploring a 29.59% Potential Upside in Non-Opioid Pain Management Solutions - DirectorsTalk Interviews
Behavioral Patterns of PCRX and Institutional Flows - Stock Traders Daily
PCRX Stock Down 10% as Preliminary Q4 Revenues Miss Estimates - sharewise.com
Pacira BioSciences (PCRX) Is Down 6.3% After Cut 2025 Outlook And Activist PressureHas The Bull Case Changed? - simplywall.st
Is Pacira BioSciences (NASDAQ:PCRX) Using Too Much Debt? - 富途牛牛
Bronstein, Gewirtz & Grossman, LLC Announces an Investigation Against Pacira BioSciences, Inc. (PCRX) and Encourages Stockholders to Learn More About the Investigation - ACCESS Newswire
2026-01-11 | Bronstein, Gewirtz & Grossman, LLC Announces an Investigation Against Pacira BioSciences, Inc. (PCRX) and Encourages Stockholders to Learn More About the Investigation | NDAQ:PCRX | Press Release - Stockhouse
Assessing Pacira BioSciences (PCRX) Valuation After Record EXPAREL Quarter Buybacks And Activist Pressure - Sahm
Pacira Stock (-9.6%): EXPAREL Decel Spooks the Street - Trefis
How Investors May Respond To Pacira BioSciences (PCRX) Activist Pressure Amid Buybacks And Rising EXPAREL Revenue - Yahoo Finance
Pacira BioSciences (NASDAQ:PCRX) Shares Gap DownHere's What Happened - MarketBeat
Is Pacira BioSciences Inc. (82P) stock supported by strong fundamentalsNew Releases Roundup & walk-ready comfort choices - ulpravda.ru
HC Wainwright Reaffirms Buy Rating for Pacira BioSciences (NASDAQ:PCRX) - MarketBeat
Pacira BioSciences' (PCRX) "Buy" Rating Reiterated at Needham & Company LLC - MarketBeat
Pacira BioSciences (PCRX) Rating Reiterated as 'Buy' by HC Wainw - GuruFocus
What Analysts Are Saying About Pacira BioSciences Stock - Benzinga
Pacira BioSciences (PCRX) Receives 'Buy' Rating from Needham | P - GuruFocus
Pacira BioSciences Stock Pre-Market (-9.7%): Weak Preliminary 2025 Revenue - Trefis
Will Pacira BioSciences Inc. stock benefit from AI adoptionJuly 2025 Big Picture & Growth Focused Investment Plans - Улправда
Why Pacira BioSciences Inc. stock remains resilient2025 Big Picture & Detailed Earnings Play Strategies - Улправда
Signal Recap: Will Pacira BioSciences Inc. stock continue upward momentumJuly 2025 Catalysts & Short-Term High Return Ideas - Улправда
Pacira BioSciences (PCRX) Shares Dip After Revenue Outlook Cut - GuruFocus
Pacira (PCRX) Reports Strong 2025 Performance, Eyes Future Growt - GuruFocus
Pacira reports record EXPAREL sales with 7% volume growth in Q4 By Investing.com - Investing.com South Africa
Pacira reports record EXPAREL sales with 7% volume growth in Q4 - Investing.com
Pacira Reports Preliminary Unaudited Fourth Quarter and Full-Year 2025 Revenues - The Manila Times
Tranche Update on Pacira BioSciences, Inc.'s Equity Buyback Plan announced on May 8, 2025. - MarketScreener
Is Pacira BioSciences Inc. stock dividend yield sustainableJuly 2025 Sector Moves & Free Reliable Trade Execution Plans - Улправда
Is Pacira BioSciences Inc. (82P) stock attractive post correctionShort Setup & Long-Term Growth Plans - ulpravda.ru
Bronstein, Gewirtz & Grossman, LLC Encourages Pacira BioSciences, Inc. (PCRX) Investors to Inquire about Securities Investigation - ACCESS Newswire
Pacira BioSciences to Present at the 44th Annual J.P. Morgan Healthcare Conferences - markets.businessinsider.com
1.09%
0.56%
In Yahoo öffnen
|
In Google öffnen
|
In Finviz öffnen
|
In MarketWatch öffnen
|
Öffnen Sie in EDGAR
|
Offen in Reuters
Kapitalisierung:
|
Volumen (24h):